Synlogic (NASDAQ:SYBX) Given New $13.00 Price Target at HC Wainwright

Synlogic (NASDAQ:SYBX) had its price objective reduced by HC Wainwright from $22.00 to $13.00 in a research note released on Wednesday morning, The Fly reports. They currently have a buy rating on the biotechnology company’s stock.

Several other equities analysts also recently commented on SYBX. Zacks Investment Research downgraded shares of Synlogic from a buy rating to a hold rating in a report on Wednesday, August 14th. Oppenheimer downgraded shares of Synlogic from an outperform rating to a market perform rating in a report on Tuesday, August 20th. Chardan Capital set a $25.00 target price on shares of Synlogic and gave the stock a buy rating in a report on Monday, July 15th. ValuEngine raised shares of Synlogic from a sell rating to a hold rating in a report on Thursday, August 1st. Finally, Wedbush reissued an outperform rating and issued a $20.00 target price on shares of Synlogic in a report on Friday, August 9th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and six have given a buy rating to the company’s stock. Synlogic presently has an average rating of Buy and an average price target of $16.33.

Shares of NASDAQ:SYBX opened at $3.27 on Wednesday. The company has a debt-to-equity ratio of 0.13, a current ratio of 14.43 and a quick ratio of 14.43. Synlogic has a 1-year low of $2.90 and a 1-year high of $14.59. The company has a market capitalization of $102.45 million, a P/E ratio of -1.61 and a beta of 2.39. The firm’s 50 day simple moving average is $6.17 and its two-hundred day simple moving average is $7.75.



Synlogic (NASDAQ:SYBX) last issued its quarterly earnings results on Thursday, August 8th. The biotechnology company reported ($0.45) earnings per share for the quarter, beating the consensus estimate of ($0.49) by $0.04. Synlogic had a negative net margin of 1,844.96% and a negative return on equity of 34.75%. The business had revenue of $0.35 million for the quarter, compared to the consensus estimate of $0.96 million. On average, sell-side analysts anticipate that Synlogic will post -1.92 earnings per share for the current fiscal year.

Several hedge funds have recently added to or reduced their stakes in SYBX. Bank of Montreal Can increased its position in Synlogic by 5,743.1% in the first quarter. Bank of Montreal Can now owns 12,738 shares of the biotechnology company’s stock worth $97,000 after purchasing an additional 12,520 shares during the last quarter. Parametric Portfolio Associates LLC bought a new stake in Synlogic in the second quarter worth $195,000. Charles Schwab Investment Management Inc. increased its position in Synlogic by 11.1% in the second quarter. Charles Schwab Investment Management Inc. now owns 37,208 shares of the biotechnology company’s stock worth $339,000 after purchasing an additional 3,708 shares during the last quarter. Bank of New York Mellon Corp increased its position in Synlogic by 12.1% in the fourth quarter. Bank of New York Mellon Corp now owns 56,774 shares of the biotechnology company’s stock worth $398,000 after purchasing an additional 6,129 shares during the last quarter. Finally, Alps Advisors Inc. increased its position in Synlogic by 4.5% in the first quarter. Alps Advisors Inc. now owns 61,466 shares of the biotechnology company’s stock worth $467,000 after purchasing an additional 2,658 shares during the last quarter. 66.08% of the stock is currently owned by hedge funds and other institutional investors.

Synlogic Company Profile

Synlogic, Inc a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its lead therapeutic programs include SYNB1020, an oral therapy for the treatment of hyperammonemia, which includes patients with liver diseases, such as hepatic encephalopathy, as well as patients with urea cycle disorders; and SYNB1618, an oral therapy that is in Phase I/IIa clinical trial to treat phenylketonuria.

Recommended Story: Options Trading – Understanding Strike Price

The Fly

Analyst Recommendations for Synlogic (NASDAQ:SYBX)

Receive News & Ratings for Synlogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synlogic and related companies with MarketBeat.com's FREE daily email newsletter.